Evidence map›Paper›PMID 41625777›Full record

ArticleInternational journal of pharmaceutics: X2026

Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small cell lung cancer.

Salman M Ghazwani, Sami Alhazmi, Salhah M Ghazwani, Hussam M Shubaily, Ahmed M Wafi, Naifa Alenazi, Marwa Qadri, Amal Naif Alshammari, Wedad Mawkili, Jobran M Moshi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Vismodegib-loaded ufasomes inhaler for treatment of non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Salman M GhazwaniDepartment of Surgery, Faculty of Medicine, Jazan University, Saudi Arabia.
Sami AlhazmiDepartment of Pediatrics, Faculty of Medicine, Jazan University, Saudi Arabia.
Salhah M GhazwaniPaediatric Department, King Fahad Central Hospital-Jazan, Jazan Health Cluster, Saudi Arabia.
Hussam M ShubailyDepartment of Basic Medical sciences (Pathology), Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Ahmed M WafiBasic Medical Science Department, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.
Naifa AlenaziDepartment of Pharmaceutical Science, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
Marwa QadriDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, postal code, 45142, Saudi Arabia.
Amal Naif AlshammariBiology Department, Darb University College, Jazan University, Saudi Arabia.
Wedad MawkiliDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Jobran M MoshiDepartment of Medical Laboratory Technology, College of Nursing and Health Science, Jazan University, Jazan, Saudi Arabia.
Zenat KhiredSurgical department, faculty of medicine, Jazan University, Saudi Arabia.
Salama A SalamaDepartment of Biology, College of Science, Jazan University, P.O. Box. 114, Jazan 45142, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety and effectiveness of nintedanib in treating non-small cell lung cancer (NSCLC) have been evaluated in several clinical trials. However, nintedanib exhibits low oral bioavailability due to its poor solubility and first-pass metabolism. To enhance the sustainability, targeting, bioavailability, and effectiveness of nintedanib, a targeted therapy for NSCLC was developed in the form of nebulized nintedanib ufasomes (NLU). Various NLU formulations were optimized utilizing the Design Expert software. The selected NLU was then evaluated for its aerodynamics, cytotoxicity, bioavailability, and targeting capabilities. To evaluate the effectiveness and safety of the optimal NLU formulation, a dose-dependent study was conducted using a mouse model of lung cancer induced by Lewis lung carcinoma (LLC) cell lines. The selected NLU formulation increased the sustainability, bioavailability, and targeting capability of nintedanib by 49.5 %, 6.63-fold, and 8.99-fold, respectively. Additionally, it decreased the IC

Indexed as

BioavailabilityLewis lung carcinomaLung cancerNintedanibTargeting

Identifiers

PMID41625777
PMCPMC12856854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.